Baseline comorbidities and medication lists were screened for chronic immune-mediated inflammatory diseases with known IL-17 activation (e.g., psoriasis, rheumatoid arthritis) and for IL-17/IL-23–targeted biologics. This evidence concerns the gene IL17A and psoriasis.